Publication

Our latest study, published in Cell Reports Medicine, uncovers an unexpected intracellular role for lysyl oxidase (LOX), traditionally known as an extracellular matrix regulator, in maintaining mitochondrial homeostasis and protecting triple-negative breast cancer (TNBC) cells from ferroptosis. Pharmacological inhibition of LOX with our best-in-class inhibitor, LXG6403, disrupts mitochondrial homeostasis and weakens Read more

Our latest article has been published in Nature Communications. The study focuses on the identification of lysyl oxidase (LOX) protein as a major chemotherapy resistance modulator in triple negative breast cancer. We showed that targeting LOX overcomes chemoresistance in TNBC. Read the article here.